Last $462.77 MXN
Change Today 0.00 / 0.00%
Volume 0.0
PFE* On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 4:09 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE*) Snapshot

Open
$467.81
Previous Close
$462.77
Day High
$467.81
Day Low
$462.70
52 Week High
12/11/14 - $469.94
52 Week Low
08/12/14 - $369.18
Market Cap
2.9T
Average Volume 10 Days
3.9K
EPS TTM
--
Shares Outstanding
6.3B
EX-Date
02/4/15
P/E TM
--
Dividend
$1.12
Dividend Yield
2.97%
Current Stock Chart for PFIZER INC (PFE*)

pfizer inc (PFE*) Details

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company’s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company’s Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd.; and strategic collaboration with iTeos Therapeutics SA. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

77,700 Employees
Last Reported Date: 02/28/14
Founded in 1849

pfizer inc (PFE*) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.2M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.1M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $926.3K
Group President of Global Established Pharma ...
Total Annual Compensation: $810.1K
Compensation as of Fiscal Year 2013.

pfizer inc (PFE*) Key Developments

Bristol-Myers Squibb Company and Pfizer Announce Positive Results from Anticoagulant Study

Bristol-Myers Squibb Company and Pfizer Inc. have announced results from a human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates, or PCCs, in healthy subjects. The study results demonstrated that both PCCs, Sanquin's Cofact (a heparin-free formulation) and CSL Behring's Beriplex P/N (a formulation containing heparin) reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential (ETP). Eliquis is a novel oral anticoagulant that specifically inhibits Factor Xa. This study evaluated the effect of two non-activated 4-factor PCCs, Cofact and Beriplex P/N, on Eliquis pharmacodynamics and pharmacokinetics in healthy subjects. Cofact and Beriplex P/N are used to stop severe bleeding in patients taking vitamin K antagonists, such as warfarin, or with a blood clotting factor deficiency. Currently there are no approved reversal agents for Eliquis or other direct Factor Xa inhibitors. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects (mean age 33+7 years). Within each period, subjects received Eliquis 10 mg twice daily. On day four (after steady-state was achieved), three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. The mean Eliquis pharmacokinetic profiles were consistent across all treatment groups and were not affected by PCC administration. Following completion of the 30-minute Cofact infusion, the effect of Eliquis on ETP was significantly reduced compared to placebo (p 0.05). Mean ETP was comparable to the day four Eliquis pre-dose value (steady-state trough Eliquis concentration) at the end of the Cofact infusion and 30 minutes after completing the Beriplex P/N infusion. Mean ETP was within the baseline value (Eliquis naive) within 5.5 hours after completing the infusion for both PCCs. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.

Pfizer Inc.(NYSE:PFE) dropped from S&P 500 Growth Index

Pfizer Inc.(NYSE:PFE) dropped from S&P 500 Growth Index

Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia

Pfizer Inc. announced top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN). The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in pain reduction. PHN is a type of peripheral neuropathic pain caused by nerve damage. Symptoms include continued burning or electric shock-like pain. This study is the final of three Phase 3 studies of the pregabalin CR formulation conducted to ascertain the potential use of pregabalin as a once-a-day therapy. The first study in adults with partial onset seizures with epilepsy did not meet its primary endpoint. In the second study in patients with fibromyalgia, pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to LTR in pain reduction.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE*:MM $462.77 MXN 0.00

PFE* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $166.26 USD -0.70
Bayer AG €114.86 EUR -0.61
Gilead Sciences Inc $93.79 USD +2.50
Novartis AG SFr.92.35 CHF -1.20
Procter & Gamble Co/The $93.46 USD +0.32
View Industry Companies
 

Industry Analysis

PFE*

Industry Average

Valuation PFE* Industry Range
Price/Earnings 19.6x
Price/Sales 4.0x
Price/Book 2.6x
Price/Cash Flow 13.6x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.